替地唑胺、利奈唑胺与万古霉素模拟人ELF暴露在葡萄球菌肺炎小鼠模型中的疗效比较
在免疫抑制与免疫正常小鼠金黄色葡萄球菌肺炎模型中,比较替地唑胺、利奈唑胺和万古霉素模拟人上皮衬液暴露的疗效。替地唑胺在两个模型中均显示持续杀菌效果,优于万古霉素,与利奈唑胺无统计学差异。
要点
- 替地唑胺模拟人ELF暴露在免疫抑制和免疫正常小鼠肺炎模型中均显示持续疗效。
- 替地唑胺的细菌减少优于万古霉素,与利奈唑胺无统计学显著差异。
- 结果需在患者中验证。
核心结论
- 替地唑胺模拟人ELF暴露在免疫抑制和免疫正常肺炎模型中均显示持续疗效。
- 替地唑胺在两个模型中细菌减少均大于万古霉素,与利奈唑胺无统计学显著差异。
研究设计与样本
- 研究8株金黄色葡萄球菌(4株MRSA和4株MSSA)。
- 免疫抑制与免疫正常小鼠分别经鼻接种107和109 cfu/mL菌液,治疗至72小时。
- 替地唑胺、利奈唑胺和万古霉素采用模拟临床剂量后人ELF暴露的模型特异性方案。
- 在24、48或72小时处死小鼠,比较肺内log10 cfu变化与0小时对照。
主要发现
- 免疫抑制小鼠0小时平均细菌负荷为5.81 log10 cfu/肺,免疫正常小鼠为8.17 log10 cfu/肺。
- 未治疗时24小时细菌负荷分别增至7.97和9.00 log10 cfu/肺。
- 免疫抑制小鼠72小时替地唑胺细菌密度变化为-2.69 ± 0.62 log10 cfu/肺。
- 免疫正常小鼠72小时替地唑胺细菌密度变化为-3.57 ± 0.88 log10 cfu/肺。
- 两个模型中替地唑胺细菌减少均大于万古霉素,与利奈唑胺无统计学显著差异。
临床怎么用
- 替地唑胺模拟人ELF暴露在免疫抑制宿主中显示持续疗效,支持进一步临床验证。
局限性
- 结果来自小鼠模型,需在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Few antibiotics are approved to treat Staphylococcus aureus pneumonia. Tedizolid is an oxazolidinone with potent in vitro activity against S. aureus and is currently under investigation for hospital-acquired and ventilator-associated bacterial pneumonia. Limited data exist on the comparative efficacy of tedizolid versus current first-line treatments vancomycin and linezolid in the compromised host. Our objective was to compare the efficacy of human-simulated epithelial lining fluid (ELF) exposures of tedizolid, linezolid and vancomycin against S. aureus in neutropenic and immunocompetent murine pneumonia models. METHODS: Eight S. aureus isolates (four MRSA and four MSSA) were studied. Neutropenic and immunocompetent mice were inoculated intranasally with bacterial suspensions of 107 and 109 cfu/mL, respectively, then treated for up to 72 h with model-specific regimens of tedizolid, linezolid and vancomycin simulating human ELF exposures after clinical doses. Mice were sacrificed at 24, 48 or 72 h and changes in log10 cfu/lungs were compared with 0 h controls. RESULTS: Mean bacterial burdens at 0 h were 5.81 and 8.17 log10 cfu/lungs for neutropenic and immunocompetent mice, respectively, and increased at 24 h in the absence of antibiotic treatment to 7.97 and 9.00 log10 cfu/lungs, respectively. In neutropenic and immunocompetent mice, tedizolid was associated with bacterial density changes of -2.69 ± 0.62 and -3.57 ± 0.88 log10 cfu/lungs at 72 h, respectively. In both models, tedizolid treatment produced greater bacterial reductions than vancomycin and was not statistically significantly different from linezolid. CONCLUSIONS: Human-simulated ELF exposures of tedizolid demonstrated sustained efficacy in compromised and competent models of pneumonia. Validation of these findings in patients is warranted.
引用
- Kidd JM, Abdelraouf K, Nicolau DP, et al. Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia. J Antimicrob Chemother. 2019. PMID: 30561650. doi:10.1093/jac/dky513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。